Comparison · NCT02764541-58d6bf70
Arm C Endocrine With Palbociclib vs Arm D Endocrine Therapy Alone: Number of Participants With RCB Response in Arm C and Arm D During the Treatment Phase
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm C Endocrine With Palbociclib vs Arm D Endocrine Therapy Alone: Number of Participants With RCB Response in Arm C and Arm D During the Treatment Phase. Trial comparisons, record NCT02764541-58d6bf70. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02764541-58d6bf70
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0781 | 0.043 | 0.138 | wilson | |
| Risk in group 2 | 0.05 | 0.0171 | 0.137 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0281 | -0.0657 | 0.0963 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.56 | 0.446 | 5.47 | log | |
| Odds ratio, group 1 over group 2 | 1.61 | 0.427 | 6.08 | log | |
| Number needed to treat, for one more participant with the outcome on Arm C Endocrine With Palbociclib than on Arm D Endocrine Therapy Alone | 35.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm C Endocrine With Palbociclib | Endocrine therapy in combination with Palbociclib are given in the treatment phase for 24 weeks. | 10 | 128 | OG000 |
| Group 2 | Arm D Endocrine Therapy Alone | Endocrine therapy alone is given in the treatment phase for 24 weeks | 3 | 60 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With RCB Response in Arm C and Arm D During the Treatment Phase
- Description
RCB response is defined as RCB-0 or RCB-I; RCB not response is defined as RCB-II or RCB-III Residual Cancer Burden (RCB) considers residual disease in the tumor bed and lymph nodes after NAC, generating a continuous score which is then grouped into four categories: RCB-0, RCB-I, RCB-II and RCB-III. Higher RCB group reflects more tumor burden remaining, thus worse outcome
- Time frame
- day 15 to 24 weeks
- Population
- Patients with treatment and surgery are included into the analysis population
Source ClinicalTrials.gov
Trial
- Title
- Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
- NCT number
- NCT02764541
- Phases
- PHASE2
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Tamoxifen, Palbociclib, Endocrine Therapy
- Lead sponsor
- Dana-Farber Cancer Institute
- Results first posted
- 2023-08-31
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02764541?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02764541-58d6bf70